CG Oncology, Inc. Common stock (CGON) — Cash Flow-to-Debt Ratio
CG Oncology, Inc. Common stock (CGON) has a Cash Flow-to-Debt Ratio of -0.93x as of December 2025, meaning its operating cash flow of $-36.22 Million could theoretically repay -1% of its total liabilities ($38.99 Million) in one year. See CGON working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CG Oncology, Inc. Common stock Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for CG Oncology, Inc. Common stock across 5 annual periods. Also explore CGON year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for CG Oncology, Inc. Common stock (2021–2025)
Year-by-year debt coverage analysis for CG Oncology, Inc. Common stock. For market capitalisation and broader financial context, see CGON market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.39x | $-132.35 Million | $38.99 Million | ▲ +7.6% |
| 2024 | -3.67x | $-78.71 Million | $21.42 Million | ▼ -16.7% |
| 2023 | -3.15x | $-45.68 Million | $14.51 Million | ▼ -138.4% |
| 2022 | -1.32x | $-29.80 Million | $22.57 Million | ▼ -78.3% |
| 2021 | -0.74x | $-13.65 Million | $18.44 Million | — |